Immunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Using its technologies, the Company has built a pipeline of nine clinical-stage product candidates. Its advanced product candidate is 90Y-clivatuzumab tetraxetan. It initiated a Phase III registration trial in January 2014 in patients with advanced pancreatic cancer. Its portfolio of wholly owned product candidates also includes antibody-drug conjugates (ADCs). Its advanced ADCs are IMMU-132 and IMMU-130, which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and pre-clinical development.